Any silver bullet to boost stock price from $13 to $263 in
seven years? The recipe to create this
flashy record for Valeant Pharmaceuticals is savage, i.e., hostile takeover of
the other companies followed by dismissing majority of the employees, slashing
R&D funding down to almost zero and raising the drug price of the acquired company
substantially. Valeant, now under
investigation by SEC due to its alleged accounting fraud, has a blatant hostile
acquisition record: acquired Medicis
Pharmaceuticals and dismissed 95% of Medicis’s 790 full-time employees; acquired Bausch & Lomb and slashed 27% of
its 4,100 employees; acquired Salix and
43% of Salix’s 977 full-time employees
were let go. http://www.bloomberg.com/news/articles/2016-03-03/valeant-s-boss-is-back-can-the-ceo-save-the-day-again
No comments:
Post a Comment